Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of around 20 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb

UCB FY Consensus Product Sales Estimates (Average)

In € million 2020a 2021e 2022e 2023e  2024e  2025e  2026e Peak Sales NPV
Core Products                  
Cimzia 1,799 1,868 1,933 1,961 1,867 1,593 1,345   5,463
Vimpat 1,451 1,535 953 636 546 493 441   2,076
Keppra  788 848 709 630 572 527 485   2,219
Briviact 288 351 421 488 547 595 565 625 1,735
Neupro 311 299 261 228 198 174 157   648
New Products
(global sales, non-risk adj.)
                 
Evenity    473 649 802 936 1,047 1,123 1,388 2,248
Nayzilam 26  49 75 97 116 130 136 172 419
Potential new Product Launches
(global sales, non-risk adj.)
                 
Bimzelx    43 291 625 1,016 1,422 1,816 2,872 7,724
Zilucoplan   0 8 111 269 421 575 1,076 1,927
Rozanolixizumab    0 8 78 200 348 516 1,109 1,493
Dapimab   0 0 1 5 39 129    
Staccato alprazolam   0 0 4 28 79 122    
Bepranemab   0 0 19 59 148 239    

 

UCB FY Consensus Earnings Estimates (Average)

In € million 2020a 2021e 2022e 2023e  2024e 2025e
Net Sales 5,052   5,356  5,028  5,176 5,592  5,901 
Revenue 5,347   5,624 5,283  5,423  5,832  6,139 
Adjusted EBIT 1,093   1,225 1,097  1,211  1,475   1,675
Adjusted EBITDA 1,441   1,577 1,444  1,583  1,852  2,051 
Net Profit*  732  969  847  950  1,181  1,353 
Core EPS (€) 5.36  5.95 5.30 5.89 7.10  8.02 

*attributable to UCB shareholders  

UCB FY Consensus Product Sales Estimates (Median)

In € million 2020a 2021e 2022e 2023e  2024e  2025e  2026e Peak Sales NPV
Core Products                  
Cimzia 1,799 1,855 1,940 1,978 1,863 1,538 1,313   5,126
Vimpat 1,451 1,534 952 618 538 483 417   2,192
Keppra  788 870 721 636 572 526 485   2,070
Briviact 288 349 420 490 553 590 569 616 1,677
Neupro 311 301 254 214 192 174 156   559
New Products
(global sales, non-risk adj.)
                 
Evenity    468 680 810 927 1,051 1,081 1,328 2,323
Nayzilam 26  49 74 94 113 130 136 160 430
Potential new Product Launches
(global sales, non-risk adj.)
                 
Bimzelx   36 292 627 1,021 1,378 1,766 2,632 6,539
Zilucoplan   0 0 95 259 416 552 1,063 1,915
Rozanolixizumab    0 0 78 194 348 540 1,020 1,601
Dapimab   0 0 0 0 37 88    
Staccato alprazolam   0 0 0 24 66 83    
Bepranemab   0 0 0 3 75 168    

 

UCB FY Consensus Earnings Estimates (Median)

In € million 2020a 2021e 2022e 2023e  2024e 2025e
Net Sales 5,052  5,347  5,041  5,201 5,644   5,943
Revenue 5,347  5,628  5,286   5,454 5,886  6,212 
Adjusted EBIT 1,093  1,222  1,118  1,248  1,480 1,633 
Adjusted EBITDA 1,441  1,572 1,431  1,613  1,878   2,019
Net Profit*  732  966  849  949  1,189 1,327
Core EPS (€) 5.36  5.95 5.40  5.94  7.22  7.97 

*attributable to UCB shareholders

Downloads:
UCB FY Consensus (Excel)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated 20 September 2021



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.